Results 91 to 100 of about 10,975 (245)
Anàlisi del títol d'anticossos anti-achr i la seva correlació clínica en pacients amb miastenia gravis seropositiva [PDF]
, 2013 Els anticossos contra el receptor de l'acetilcolina representen el principal mecanisme patogènic en la Miastènia Gravis, però la seva utilitat com a biomarcador durant el seguiment de la malaltia és ...
Illa Sendra, I. +3 more
core +1 more source
Quality of life and life circumstances in German myasthenia gravis patients [PDF]
, 2010 Background Myasthenia gravis (MG) is a chronic neuromuscular disease. Advances in medical therapy have continuously increased the life expectancy of MG patients, without definitively curing the disease.
Sabine Twork +4 more
core +2 more sources
Facial expression recognition for emotion perception: A comprehensive science mapping
Ibrain, Volume 12, Issue 1, Page 38-51, Spring 2026.Facial expression recognition (FER) has emerged as a pivotal interdisciplinary research domain, bridging computer science, psychology, neuroscience, and medicine. By mapping the FER scientific knowledge graph, the study aimed to explore the technological evolution and forecast future application trends in this field.
Hou‐Ming Kan +10 more
wiley +1 more source
Digestive Endoscopy, Volume 38, Issue 3, March 2026.ABSTRACT Objectives Sedation during colonoscopy is becoming increasingly important. Remimazolam, an ultra‐short‐acting benzodiazepine, has a shorter pharmacokinetic half‐life than that of midazolam. This study examined whether remimazolam provides superior sedation during colonoscopy in Japanese patients.
Daisuke Yamaguchi +18 more
wiley +1 more source
Miasthenia gravis in pediatric age
Acta Médica del Centro, 2008 Background: Myasthenia gravis is an autoimmune disorder characterized by fluctuating muscle weakness and fatigue of different muscle groups, secondary to a synaptic transmission alteration caused by the blockade and destruction of the acetylcholine ...
Liubka María Pérez Mederos +3 more
doaj
European Journal of Neurology, Volume 33, Issue 3, March 2026.Conceptual framework supporting Minimal Symptom Expression (MSE) as a patient‐centric treatment goal in generalized myasthenia gravis. Guidelines prioritize minimal manifestations (MM) or better (MGFA‐PIS); MM is clinician‐judgment based and not instrument‐defined. MSE (MG‐ADL 0‐1) is standardized, actionable, and widely used. Across Phase III programs
Andreas Meisel +5 more
wiley +1 more source
Ocular sequelae from the illicit use of class A drugs [PDF]
, 2004 Aim: To highlight the changes that may take place in the visual system of the class A drug abuser. Methods: A literature review was carried out of ocular/visual sequelae of the more common class A drugs.
Firth, A.Y.
core
European Journal of Neurology, Volume 33, Issue 3, March 2026.This prospective cohort study identifies independent predictors of relapse following complete treatment discontinuation in 196 myasthenia gravis (MG) patients who achieved minimal symptom expression (MSE). Cox regression analysis revealed late‐onset MG (age ≥ 50 years) as a risk factor, while rituximab therapy, longer treatment duration, and extended ...
Dingxian He +7 more
wiley +1 more source
Treatment of Ocular Myasthenia Gravis
Asia-Pacific Journal of Ophthalmology, 2019 Myasthenia gravis is a relatively common neuromuscular disorder, with ocular myasthenia gravis being a subset defined as myasthenia gravis limited to the orbicularis, levator, and extraocular muscles. Patients with ocular myasthenia gravis can have disabling diplopia or functional blindness from ptosis and in most cases treatment is required.
openaire +2 more sources
European Journal of Neurology, Volume 33, Issue 3, March 2026.This population‐based case–control study using the Clalit Health Services database (Israel) evaluated adults ≥ 18 years (2020–2022) to assess the risk of new‐onset myasthenia gravis (MG) following confirmed SARS‐CoV‐2 infection or Pfizer‐BioNTech (BNT162b2) vaccination.
Tasneem Kab +6 more
wiley +1 more source